Literature DB >> 10698206

Regulation of the Na,K-pump by leptin in 3T3-L1 fibroblasts.

G Sweeney1, W Niu, R Kanani, A Klip.   

Abstract

Leptin, the product of the obesity (ob) gene, controls energy intake and expenditure primarily by actions on the central nervous system. However, recently it has become apparent that leptin also elicits a growing and diverse array of effects on peripheral tissues. The Na,K-pump is an electrogenic plasma membrane protein which actively extrudes 3Na+ ions and imports 2K+ ions per molecule of ATP hydrolysed. The pump is responsible for the maintenance of the electrochemical potential of all cells, which in turn drives all ion-coupled transport mechanisms. In this study we use 3T3-L1 fibroblasts to show that leptin inhibits Na,K-pump activity, as assessed by ouabain-sensitive 86Rb+ uptake. Inhibition of the Na,K-pump correlated with increased serine phosphorylation of the catalytic Na,K-pump alpha1 subunit. Upon investigation of leptin-stimulated signalling pathways using specific pharmacological inhibitors, only wortmannin prevented inhibition of the Na,K-pump by leptin. Moreover, leptin stimulated phosphotyrosine-associated PI 3-kinase activity in these cells. In summary, leptin was found to inhibit Na,K-pump activity, likely via PI 3-kinase. We propose that this effect may have wide ranging cardiovascular and metabolic implications and perhaps explain physiological effects of the hormone such as natriuresis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698206     DOI: 10.1210/endo.141.3.7440

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  2 in total

1.  Effect of vanadium on renal Na+,K+-ATPase activity in diabetic rats: a possible role of leptin.

Authors:  Mohamed D Morsy; Hesham A Abdel-Razek; Osama M Osman
Journal:  J Physiol Biochem       Date:  2010-10-07       Impact factor: 4.158

2.  Leptin inhibits glucose intestinal absorption via PKC, p38MAPK, PI3K and MEK/ERK.

Authors:  Ola El-Zein; Sawsan Ibrahim Kreydiyyeh
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.